A review in the Journal of Translational Medicine argues that metabolism-focused engineering could be a path to make CAR-T cells work better in solid tumors. It outlines how tumor nutrient environments, oxygen gradients, and energy depletion can blunt CAR-T activity, and it surveys strategies aimed at rewiring metabolic checkpoints to sustain effector function. The paper situates metabolism as a concrete engineering lever rather than only a microenvironment narrative. It also summarizes emerging approaches that combine CAR design with metabolic support or metabolic pathway control to extend activity beyond the early response phase. For sponsors and biotech teams, the review highlights where preclinical designs can be translated into actionable development plans for solid tumor CAR-T differentiation.